BioMarin Pharmaceutical Inc. (BMRN) Key Metrics
BMRN valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $10.58B
- Enterprise value
- $15.37B
- P/E (TTM)
- 147.8 10-yr median 33.6
- Forward P/E
- 9.4
- PEG ratio
- 0.36
- Price / sales
- 3.1 10-yr median 9.0
- Price / book
- 1.9 10-yr median 4.2
- EV / EBITDA
- 39.8 10-yr median 120.7
- Dividend yield
- —
- Beta
- 0.21
BMRN key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsBMRN valuation Price multiples at each fiscal year-end price.
BMRN returns How much profit the business earns on the capital it uses.
BMRN per-share figures Results divided by the shares outstanding at year-end.
BMRN financial health Debt, liquidity and how easily interest is covered.
BMRN efficiency & capital use Working capital cycle and where the cash goes.
BMRN valuation history
BMRN returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
BMRN debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
BMRN cash returned to shareholders
BMRN price vs earnings per share
BMRN key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $11.73B | $12.93B | $18.47B | $19.56B | $16.15B | $16.81B | $15.14B | $15.09B | $15.55B | $13.77B |
| Enterprise value | $10.81B | $12.44B | $18.50B | $19.36B | $16.23B | $16.83B | $15.24B | $14.84B | $15.33B | $13.66B |
| P/E ratio | 33.6 | 30.3 | 110.2 | 138.1 | — | 19.7 | — | — | — | — |
| Price / sales | 3.6 | 4.5 | 7.6 | 9.3 | 8.8 | 9.0 | 8.9 | 10.1 | 11.8 | 12.3 |
| Price / book | 1.9 | 2.3 | 3.7 | 4.2 | 3.8 | 4.1 | 4.8 | 5.1 | 5.5 | 5.0 |
| Price / free cash flow | 16.2 | 27.2 | 357.7 | 355.9 | 87.2 | — | — | — | — | — |
| Price / operating cash flow | 14.2 | 22.6 | 116.0 | 111.2 | 53.0 | 196.9 | 313.7 | 747.0 | — | — |
| EV / sales | 3.4 | 4.4 | 7.6 | 9.2 | 8.8 | 9.0 | 8.9 | 10.0 | 11.7 | 12.2 |
| EV / EBITDA | 18.9 | 19.1 | 60.3 | 72.9 | 342.2 | 201.2 | 477.6 | — | 168.5 | — |
| EV / free cash flow | 14.9 | 26.2 | 358.1 | 352.3 | 87.6 | — | — | — | — | — |
| Earnings yield | 3.0% | 3.3% | 0.9% | 0.7% | −0.4% | 5.1% | −0.2% | −0.5% | −0.8% | −4.6% |
| Free cash flow yield | 6.2% | 3.7% | 0.3% | 0.3% | 1.1% | −0.3% | −0.6% | −0.8% | −1.3% | −2.7% |
| Dividend yield | — | — | — | 0.1% | 0.0% | 0.4% | 0.1% | — | 0.0% | 0.0% |
| Shareholder yield (dividends + buybacks) | — | 0.6% | 0.4% | 0.4% | 0.3% | 0.7% | 0.4% | 0.2% | 0.2% | 0.4% |
| Share price at fiscal year-end | $59.43 | $65.73 | $96.42 | $103.49 | $88.35 | $87.69 | $84.55 | $85.15 | $89.17 | $82.84 |
| Per share | ||||||||||
| Revenue per share | $16.32 | $14.51 | $12.63 | $11.09 | $10.10 | $9.71 | $9.52 | $8.41 | $7.53 | $6.72 |
| Earnings per share | $1.77 | $2.17 | $0.87 | $0.75 | −$0.35 | $4.46 | −$0.13 | −$0.44 | −$0.67 | −$3.79 |
| Operating cash flow per share | $4.19 | $2.91 | $0.83 | $0.93 | $1.67 | $0.45 | $0.27 | $0.11 | −$0.05 | −$1.37 |
| Free cash flow per share | $3.67 | $2.42 | $0.27 | $0.29 | $1.01 | −$0.27 | −$0.54 | −$0.70 | −$1.19 | −$2.26 |
| Cash per share | $7.91 | $5.78 | $5.60 | $6.83 | $5.54 | $5.56 | $4.21 | $6.12 | $8.00 | $4.75 |
| Book value per share | $30.84 | $28.76 | $25.84 | $24.36 | $23.36 | $21.42 | $17.44 | $16.74 | $16.10 | $16.64 |
| Tangible book value per share | $28.76 | $26.47 | $23.28 | $21.53 | $20.16 | $18.22 | $13.79 | $12.86 | $12.01 | $12.13 |
| Dividends per share | — | — | — | $0.08 | $0.02 | $0.38 | $0.06 | — | $0.00 | $0.00 |
| Capex per share | $0.52 | $0.50 | $0.56 | $0.64 | $0.65 | $0.72 | $0.81 | $0.82 | $1.14 | $0.89 |
| Debt per share | $3.26 | $3.30 | $5.72 | $5.79 | $5.96 | $5.67 | $4.80 | $4.68 | $6.73 | $4.11 |
| Shares outstanding | 197.4M | 196.7M | 191.6M | 189.0M | 182.9M | 191.7M | 179.0M | 177.3M | 174.4M | 166.2M |
| Change in shares outstanding | +0.3% | +2.7% | +1.4% | +3.3% | −4.6% | +7.1% | +1.0% | +1.6% | +4.9% | +3.9% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 5.9% | 8.0% | 3.5% | 3.2% | −1.5% | 23.6% | −0.8% | −2.7% | −4.2% | −24.4% |
| Return on invested capital (ROIC) | 7.5% | 7.5% | 3.5% | 3.5% | −1.5% | −0.9% | −2.7% | −3.7% | −0.4% | −24.7% |
| Return on assets (ROA) | 4.8% | 6.2% | 2.5% | 2.3% | −1.1% | 16.2% | −0.5% | −1.7% | −2.7% | −16.3% |
| Return on tangible assets | 4.9% | 6.5% | 2.6% | 2.4% | −1.2% | 16.3% | −0.6% | −2.1% | −3.0% | −19.3% |
| Free cash flow margin | 22.5% | 16.7% | 2.1% | 2.6% | 10.0% | −2.8% | −5.7% | −8.3% | −15.8% | −33.7% |
| Income quality (OCF / net income) | 2.37 | 1.34 | 0.95 | 1.24 | — | 0.10 | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $642.9M | $649.5M | $1.10B | $1.09B | $1.09B | $1.09B | $858.8M | $830.4M | $1.17B | $683.2M |
| Cash & short-term investments | $1.56B | $1.14B | $1.07B | $1.29B | $1.01B | $1.07B | $753.8M | $1.08B | $1.40B | $789.7M |
| Net debt | −$917.7M | −$488.2M | $21.9M | −$198.1M | $75.7M | $21.5M | $105.0M | −$253.9M | −$221.5M | −$106.4M |
| Debt / equity | 0.11 | 0.11 | 0.22 | 0.24 | 0.26 | 0.26 | 0.28 | 0.28 | 0.42 | 0.25 |
| Debt / assets | 0.08 | 0.09 | 0.16 | 0.17 | 0.18 | 0.19 | 0.18 | 0.19 | 0.25 | 0.17 |
| Net debt / EBITDA | −1.60 | −0.75 | 0.07 | −0.75 | 1.60 | 0.26 | 3.29 | — | −2.43 | — |
| Current ratio | 5.21 | 5.33 | 2.51 | 4.67 | 4.21 | 4.76 | 2.08 | 3.93 | 2.70 | 3.24 |
| Quick ratio | 3.50 | 3.29 | 1.57 | 3.15 | 2.77 | 3.34 | 1.35 | 2.92 | 2.12 | 2.43 |
| Interest coverage | 48.9 | 38.2 | 10.7 | 10.1 | -5.4 | -1.5 | -4.3 | -2.8 | -0.3 | -20.3 |
| Working capital | $3.19B | $2.63B | $1.78B | $2.16B | $1.73B | $1.85B | $1.01B | $1.53B | $1.39B | $982.5M |
| Invested capital | $5.17B | $5.17B | $4.97B | $4.41B | $4.35B | $4.13B | $3.23B | $2.71B | $2.59B | $2.66B |
| Tangible asset value | $5.68B | $5.21B | $4.46B | $4.07B | $3.69B | $3.49B | $2.47B | $2.28B | $2.09B | $2.02B |
| Net current asset value | $2.45B | $1.90B | $1.07B | $979.5M | $541.8M | $600.2M | $374.5M | $597.0M | $382.7M | $164.4M |
| Graham number | $35.02 | $37.48 | $22.56 | $20.26 | — | $46.34 | — | — | — | — |
| Graham net-net per share | $7.01 | $4.67 | $1.11 | $1.65 | −$0.28 | $0.05 | −$1.06 | $0.83 | $0.03 | −$0.77 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | $15.1M | $3.4M | $71.9M | $11.1M | — | $0 | $0 |
| Share buybacks (net) | — | $77.6M | $76.3M | $54.3M | $45.8M | $50.0M | $42.7M | $35.9M | $33.5M | $59.5M |
| Dividend payout ratio | — | — | — | 10.6% | — | 8.4% | — | — | — | — |
| Dividends + buybacks / free cash flow | — | 16.3% | 147.8% | 126.2% | 26.5% | — | — | — | — | — |
| Capex / revenue | 3.2% | 3.4% | 4.4% | 5.8% | 6.5% | 7.4% | 8.5% | 9.7% | 15.2% | 13.3% |
| Capex / operating cash flow | 12.4% | 17.0% | 67.6% | 68.8% | 39.1% | 161.1% | 300.5% | 715.7% | — | — |
| Capex / depreciation | 1.30 | 1.01 | 1.03 | 1.19 | 1.10 | 1.31 | 1.38 | 1.51 | 2.27 | 1.53 |
| Stock-based compensation / revenue | 5.6% | 7.1% | 8.6% | 9.4% | 10.7% | 10.2% | 9.4% | 10.0% | 10.7% | 12.1% |
| R&D / revenue | 28.6% | 26.2% | 30.9% | 31.0% | 34.1% | 33.8% | 42.0% | 46.7% | 46.5% | 59.3% |
| SG&A / revenue | 35.8% | 35.4% | 36.9% | 17.8% | 41.1% | 39.7% | 40.0% | 40.5% | 42.2% | 42.7% |
| Efficiency | ||||||||||
| Days sales outstanding | 88.9 | 82.8 | 82.6 | 72.7 | 81.2 | 81.0 | 77.1 | 73.9 | 66.2 | 62.1 |
| Days of inventory on hand | 627.0 | 735.9 | 686.4 | 606.2 | 572.2 | 480.0 | 614.9 | 582.7 | 627.2 | 545.7 |
| Days payables outstanding | 135.8 | 173.3 | 187.5 | 153.9 | 149.1 | 150.5 | 227.8 | 216.6 | 270.2 | 508.3 |
| Cash conversion cycle (days) | 580.1 | 645.4 | 581.5 | 524.9 | 504.3 | 410.4 | 464.3 | 440.0 | 423.2 | 99.5 |
| Receivables turnover | 4.11 | 4.41 | 4.42 | 5.02 | 4.49 | 4.51 | 4.73 | 4.94 | 5.51 | 5.87 |
| Payables turnover | 2.69 | 2.11 | 1.95 | 2.37 | 2.45 | 2.42 | 1.60 | 1.68 | 1.35 | 0.72 |
| Inventory turnover | 0.58 | 0.50 | 0.53 | 0.60 | 0.64 | 0.76 | 0.59 | 0.63 | 0.58 | 0.67 |
| Asset turnover | 0.44 | 0.41 | 0.37 | 0.34 | 0.31 | 0.35 | 0.37 | 0.33 | 0.30 | 0.29 |
| Average receivables | $784.4M | $647.1M | $547.5M | $417.4M | $410.9M | $412.9M | $360.0M | $302.0M | $238.3M | $190.1M |
| Average payables | $274.1M | $275.5M | $273.4M | $212.1M | $192.2M | $216.2M | $224.3M | $187.1M | $179.0M | $291.9M |
| Average inventory | $1.27B | $1.17B | $1.00B | $835.4M | $737.6M | $689.4M | $605.6M | $503.3M | $415.5M | $313.4M |
| Intangibles / total assets | 5.4% | 6.5% | 7.2% | 8.4% | 9.7% | 10.5% | 13.9% | 15.6% | 15.4% | 18.7% |
Computed from BMRN's annual financial statements (latest annual report filed February 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
BMRN valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), BioMarin Pharmaceutical traded at 33.6 times earnings, against a 10-year median of 33.6. Based on the latest twelve months, the trailing P/E is 147.8 and the forward P/E is 9.4. BioMarin Pharmaceutical earned a return on equity of 5.9% and a return on invested capital of 7.5% in fiscal 2025. It ended the year with $642.9 million of debt and $1.6 billion in cash and short-term investments, a net cash position of $917.7 million. The share count rose 18.8% from 166.2M to 197.4M over 9 years.
See the BMRN income statement, the BMRN chart for price history, or the BMRN stock overview for the latest quote and news.
BMRN key metrics FAQ
What is BioMarin Pharmaceutical's P/E ratio?
BioMarin Pharmaceutical's trailing P/E ratio is 147.8 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 9.4. At the end of fiscal 2025 it was 33.6, compared with a 10-year median of 33.6.
What is BioMarin Pharmaceutical's EV/EBITDA?
BioMarin Pharmaceutical's enterprise value was 18.9 times EBITDA at the end of fiscal 2025 (enterprise value $10.8 billion, EBITDA $572.9 million); the current EV/EBITDA is 39.8.
What is BioMarin Pharmaceutical's return on equity?
BioMarin Pharmaceutical's return on equity (ROE) was 5.9% in fiscal 2025: net income of $348.9 million on average shareholders' equity of $5.9 billion.
What is BioMarin Pharmaceutical's ROIC?
BioMarin Pharmaceutical's return on invested capital was 7.5% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does BioMarin Pharmaceutical have?
BioMarin Pharmaceutical had total debt of $642.9 million at the end of fiscal 2025, a debt-to-equity ratio of 0.11 and more cash than debt.
What is BioMarin Pharmaceutical's free cash flow yield?
BioMarin Pharmaceutical generated $725.0 million of free cash flow in fiscal 2025, a free cash flow yield of 6.2% on its market value at year-end ($11.7 billion).
What is BioMarin Pharmaceutical's current ratio?
BioMarin Pharmaceutical's current ratio was 5.21 at the end of fiscal 2025: current assets were 5.21 times current liabilities.